Europe's most valuable company, Novo Nordisk, saw a 3% increase in net profit for Q2, reaching 20 billion Danish kroner. Sales spiked by 25%, but a 5.7-billion-kroner hit was taken due to a failed hypertension treatment trial.
Novo Nordisk's net profit rose by 16% in the first half of 2024 to 45.5 billion kroner, with sales increasing by 24% to 133.4 billion kroner. The company raised its sales growth forecast for 2024 to 22-28%.
Collection
[
|
...
]